On Nov 08, major Wall Street analysts update their ratings for $Gilead Sciences (GILD.US)$, with price targets ranging from $95 to $105.
Barclays analyst Carter Gould maintains with a hold rating, and adjusts the target price from $76 to $95.
Wells Fargo analyst Mohit Bansal maintains with a buy rating, and maintains the target price at $105.
Jefferies analyst Michael Yee maintains with a buy rating, and maintains the target price at $105.
TD Cowen analyst Tyler Van Buren maintains with a buy rating, and maintains the target price at $95.
Oppenheimer analyst Matthew Biegler initiates coverage with a buy rating, and sets the target price at $105.
Furthermore, according to the comprehensive report, the opinions of $Gilead Sciences (GILD.US)$'s main analysts recently are as follows:
Gilead's recent report showed a sales surge, bolstered by robust performance across its HIV product range and surpassing expected revenues for Veklury. The strong quarter for the HIV division was marked by sustained volume expansion and a positive product mix.
The company achieved a third-quarter performance that exceeded expectations, bolstered not only by Veklury but also by Biktarvy.
The analyst expresses that a transformative period is on the horizon for Gilead, as the company is breaking away from past questionable business development decisions and returning to its foundational strength in antiviral research and development. This resurgence is highlighted by lenacapavir, which is poised to become a versatile cornerstone for HIV treatment and has the potential to broaden the applicability of PrEP beyond its traditional high-risk user base. Furthermore, the analyst points out that the PrEP market may experience substantial growth by reaching a wider audience. In the field of oncology, the company is experiencing robust growth, particularly with the drug TRODELVY, and its collaboration with a partner that may possess a leading CAR-T therapy option for multiple myeloma.
Gilead has exhibited a 'consistent steady performance' this quarter, demonstrating ongoing reliability in its HIV business. This performance is seen as a positive indicator in anticipation of the U.S. filing of lenacapavir for PrEP.
The firm acknowledged another solid quarter for Gilead and mentioned that the revised expectations are largely due to the anticipation that the Sunlenca PrEP opportunity, alongside Livdelzi in PBC, presents new commercial possibilities.
Here are the latest investment ratings and price targets for $Gilead Sciences (GILD.US)$ from 8 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
